ALX Oncology Holdings Inc at JPMorgan Healthcare Conference Transcript
&-
Good afternoon. Welcome to the JPMorgan Healthcare Conference. My name is Raji Gunasekera. I'm with the healthcare investment banking team at JPM. And today, I'm pleased to introduce the ALX Oncology team and their CEO, Jason Lettmann.
Great, thanks for having me, Raji, and thanks to JP Morgan for having us. Dangerously close to happy hour here. So appreciate you guys tuning in. Some forward looking statements and here we go.
So we are ALX Oncology where in the CD47 space, we believe we're the leader in this space and we'll go through some of the history, but very excited about and the last year coming off a great 2023 and looking forward to an outstanding year here in 2024.
So a few highlights. Last year, we were we shared the results from ASPEN-06, which is the first randomized study in the solid tumor space to show activity. In this case, in gastric cancer. And what we showed is relative to standard of care, a 30% delta
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |